Ameritas Investment Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-4,066
Closed -$75.4K 3128
2023
Q3
$75.4K Buy
4,066
+1,776
+78% +$20.1K ﹤0.01% 1848
2023
Q2
$25.3K Hold
2,290
﹤0.01% 2434
2023
Q1
$30.8K Hold
2,290
﹤0.01% 2251
2022
Q4
$36.4K Hold
2,290
﹤0.01% 2259
2022
Q3
$31K Hold
2,290
﹤0.01% 2294
2022
Q2
$31K Hold
2,290
﹤0.01% 2303
2022
Q1
$37K Hold
2,290
﹤0.01% 2242
2021
Q4
$37K Hold
2,290
﹤0.01% 2329
2021
Q3
$34K Hold
2,290
﹤0.01% 2403
2021
Q2
$46K Hold
2,290
﹤0.01% 2251
2021
Q1
$53K Hold
2,290
﹤0.01% 2057
2020
Q4
$57K Hold
2,290
﹤0.01% 1905
2020
Q3
$95K Hold
2,290
﹤0.01% 1461
2020
Q2
$110K Buy
2,290
+97
+4% +$7.49K 0.01% 1361
2020
Q1
$138K Hold
2,193
0.01% 1097
2019
Q4
$272K Buy
2,193
+81
+4% +$7.25K 0.01% 932
2019
Q3
$140K Hold
2,112
0.01% 1264
2019
Q2
$168K Buy
2,112
+304
+17% +$27.2K 0.01% 1164
2019
Q1
$202K Hold
1,808
0.01% 1048
2018
Q4
$182K Hold
1,808
0.01% 1017
2018
Q3
$228K Hold
1,808
0.01% 1013
2018
Q2
$152K Buy
+1,808
New +$132K 0.01% 1249
2014
Q2
Sell
-616
Closed -$203K 1116
2014
Q1
$203K Buy
+616
New +$208K 0.02% 968

Ameritas Investment Partners's ICPT Position: Q4 2023 in Review

Ameritas Investment Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 4,066 shares — an estimated $75.4K sold.

Ameritas Investment Partners first reported a position in ICPT in Q1 2014 and held it in 23 quarters. The position peaked at $272K in Q4 2019. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

  • Ameritas Investment Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Ameritas Investment Partners sold 4,066 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $75.4K.
  • Ameritas Investment Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 23 quarters.
  • Ameritas Investment Partners's Intercept Pharmaceuticals, Inc. position peaked at $272K in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on Ameritas Investment Partners's 13F filing for Q4 2023, filed 14 Feb 2024.